Another mid-late stage Alzheimer’s flop, this time for Lilly
Earlier this month, Roche also announced a gantenerumab Alzheimer’s failure, and last year Biogen and Eisai stopped two global Phase III trials of aducanumab.
Read More
Tag: solanezumab
Lilly’s Alzheimer’s drug fails to hit PhIII targets
Lilly has suffered a huge blow after its experimental therapy for Alzheimer’s disease failed in a large-scale Phase III trial, signifying the end of its development for patients with mild forms of the disease.
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
